Missing/wrong data?
Log in to edit
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
scientific article published on 30 August 2017
Author/s
author: Charles E de Bock, Jan Cools, Sofie Demeyer, David A Skerrett-Byrne, Nicole M Verrills, Pieter Van Vlierberghe, Matthew D Dun
Work details
Publication date
August 30, 2017
-
-
Language
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.